🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2029

Annual patent cliff calendar for 2029 — US pharmaceutical patents by expiration date.

Patents
675

Quick answer

675 indexed pharmaceutical patents have expiration dates in 2029. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 7514095

    Fabrication of drug loaded biodegradable polymer fibers

    The Board of Regents of the University of Texas System · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 7514096

    Triacylglycerols of enriched CLA content

    Aker Biomarine AS · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 7514441

    Substituted pyrazolo [1,5-A]pyrimidines as calcium receptor modulating agents

    Takeda Pharmaceutical Company Limited · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7514467

    Crystalline solids of carvedilol and processes for their preparation

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 7514414

    Suppressors of CpG oligonucleotides and methods of use

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7514434

    Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof

    Rigel Pharmaceuticals, Inc. · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7514529

    Peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccines

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7514410

    Hepatitis C therapies

    BioCryst Pharmaceuticals, Inc. · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 7514558

    Biphenyl derivatives

    Theravance, Inc. · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 7514415

    Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7517910

    Alkoxyphenylpropanoic acid derivatives

    Takeda Pharmaceutical Company Limited · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7517871

    Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders

    ACADIA Pharmaceuticals Inc. · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7517531

    Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7517895

    Synthetic diazonamides

    The Board of Regents of the University of Texas System · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7517527

    Immunotoxin with in vivo T cell suppressant activity and methods of use

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 7517865

    RNAi modulation of RSV and therapeutic uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 7517849

    Inhibition of ABC transporters by transmembrane domain analogs

    The United States of America, as represented by the Secretary, Health and Human Services · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 7517661

    Methods of screening for ligands for FPRL2

    Takeda Pharmaceutical Company Limited · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 7517858

    Prodrugs of pharmaceuticals with improved bioavailability

    The Regents of the University of California · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 7517886

    Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

    Rigel Pharmaceuticals, Inc. · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 7517971

    Muteins of human telomerase reverse transcriptase lacking telomerase catalytic activity

    The Regents of the University of Colorado · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 7517987

    Caspase inhibitors and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 7521558

    Crystalline form of a biphenyl compound

    Theravance, Inc. · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 7521049

    Use of VEGF inhibitors for treatment of eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 7521561

    Biphenyl derivatives

    Theravance, Inc. · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 7521063

    Multiple CPG oligodeoxynucleotides and their use to induce an immune response

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 7521041

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance, Inc. · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 7521054

    Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the Fv to lower the isoelectric point

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 7521414

    Polyol macrolide antitumor-antibiotics from the marine actinomycete strain CNQ140

    The Regents of the University of California · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 7521475

    Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereof

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 7521175

    Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571

    The Regents of the University of California · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 7521211

    IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 7521421

    Deuterated cyclosporine analogs and methods of making the same

    Isotechnika, Inc. · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 7521192

    EDG: modulators of lymphocyte activation and migration

    Rigel Pharmaceuticals, Inc. · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 7521545

    Azo compounds and process for production thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 7521479

    Methods of treating prion disease in mammals

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 7521535

    Anti-microbial defensin-related peptides and methods of use

    The Board of Regents for Oklahoma State University · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 7521551

    Chlorins possessing fused ring systems useful as photoselective compounds for photodynamic therapy

    Miravant Pharmaceuticals, Inc. · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 7521418

    Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent

    Theravance, Inc. · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 7521177

    Flavivirus detection methods employing recombinant antigens comprising a Japanese encephalitis (JEV) signal sequence

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 7524516

    Corrosion inhibiting mildew remover kit

    United States of America as represented by the Secretary of the Air Force · Granted Tue Apr 28 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 7524878

    Phenyl substituted carboxylic acids

    The Institute for Pharmaceutical Discovery, LLC · Granted Tue Apr 28 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 7524944

    Chimeric nucleic acids encoding polypeptides comprising CD154 and TNF-α

    The Regents of the University of California · Granted Tue Apr 28 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 7524490

    Clusterin-mediated inhibition of apoptosis via stromal bone marrow cell delivery to a cardiac site

    The Board of Regents of the University of Texas System · Granted Tue Apr 28 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 7524508

    Subgenomic replicons of the flavivirus dengue

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 28 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 7524880

    Crystalline form of a substituted pyrrolidine compound

    Theravance, Inc. · Granted Tue Apr 28 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 7524499

    Modified chimeric polypeptides with improved pharmacokinetic properties

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 28 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 7524507

    Recombinant microorganisms

    The Secretary of State for Defence in Her Brittanic Majesty's Government of the United Kingdom of Great Britain and Northern Ireland · Granted Tue Apr 28 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2029?

675 published patents in our USPTO index have expiration dates falling in calendar year 2029.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.